Focus on Diabetes

Optimizing Outcomes In Type 2 Diabetes: Integrating Longer Acting GLP-1 Receptor Agonists

March 23, 201535 min
Host: Matt Birnholz, MD

Guest: John (Jack) Leahy, MD

The goal of glycemic treatment of patients with type 2 diabetes mellitus (T2DM) is to maintain good glycemic control, while causing as few adverse consequences as possible. The choice of therapeutic agents should be based on their differing metabolic actions and side effect profiles, as well as the use of agents with complementary mechanisms of action in the likely scenario of a need for combination therapy. This has important implications for the choice of specific agents and of combinations of agents, as there are important differences between various classes of glucose-lowering agents, both beneficial, and of concern, as potential causes of adverse outcome. Treatment algorithms for T2DM are being revisited and revised to consider these differences. GLP-1-based therapies represent an important advance in the treatment of T2DM, restoring the diminished incretin effect and potentially addressing the decline in beta-cell

Chat About Optimizing Outcomes In Type 2 Diabetes: Integrating Longer Acting GLP-1 Receptor Agonists

For You